Generated by AI
Pasithea Therapeutics Corp. is a biotechnology company focused on the discovery, research, and development of innovative treatments for central nervous system disorders and RASopathies. The company’s current programs center on PAS-004, a next-generation macrocyclic MEK inhibitor being developed for indications that include neurofibromatosis type 1-associated plexiform neurofibromas and selected oncology uses. Pasithea Therapeutics Corp. also works on additional therapeutic candidates aimed at neurological and psychiatric conditions, reflecting a broader emphasis on diseases with significant unmet medical need. The company operates through therapeutic development activities and clinic-related services, positioning itself across both drug research and patient-facing healthcare applications. Based in Miami Beach, Florida, Pasithea Therapeutics Corp. plays a role in the clinical-stage biotechnology market by advancing targeted treatment candidates for complex disorders.
Website1111 Lincoln Road
Miami Beach, FL, 33139
United States
The latest articles about KTTA.
Summary of Nov 3's posts. Generated by AI.
Summary of Dec 2's posts. Generated by AI.
Summary of Nov 3's posts. Generated by AI.
Investors talking about KTTA also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.